---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-075734"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:11:52.061631+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Soleno Therapeutics Reports Q4 and Full-Year 2022 Financial Results, Provides Clinical Update

## Summary
- Enrollment nearing completion in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.
- Securities purchase agreement with Nantahala Capital, Abingworth, and Vivo Capital for up to $60 million in gross proceeds.
- Cash and cash equivalents of $14.6 million as of December 31, 2022.
- Net loss of $5.5 million for Q4 2022, compared to $2.8 million in Q4 2021.
- R&D expenses were $3.8 million for Q4 2022, compared to $3.7 million in Q4 2021.

## SEC filing metadata
- accession: 0001193125-23-075734
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/0001193125-23-075734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/d380040d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-075734
- JSON: https://secwatch.observer/filing/0001193125-23-075734.json
- Plain text: https://secwatch.observer/filing/0001193125-23-075734.txt

## Key facts
- Earnings Releases
  SOLENO THERAPEUTICS INC reported the year ended December 31, 2022 results: net income approximately $24.1 million, EPS $2.87 per basic and diluted share.
  - Period: the year ended December 31, 2022
  - Net income: approximately $24.1 million
  - EPS: $2.87 per basic and diluted share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2022, was approximately $24.1 million, or $2.87 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/0001193125-23-075734-index.htm
- Earnings Releases
  SOLENO THERAPEUTICS INC reported the fourth quarter ended December 31, 2022 results: net income approximately $5.5 million, EPS $0.58 per basic and diluted share.
  - Period: the fourth quarter ended December 31, 2022
  - Net income: approximately $5.5 million
  - EPS: $0.58 per basic and diluted share
  - Result: reported results
  source text: Net loss was approximately $5.5 million, or $0.58 per basic and diluted share, for the quarter ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/0001193125-23-075734-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.